Table 1. Characteristics of all included studies in this meta-analysis.
Study | Country | Publication | Genotyping method | Number of patient | Treatment | toxicities | Median follow-up | specimen |
---|---|---|---|---|---|---|---|---|
Sweeney, et al. [17] | America | 2000 | PCR-RFLP | 240 | chemotherapy + radiotherapy, chemotherapy, radiotherapy | NP | 58 months | tissue |
Yang, et al. [29] | China | 2005 | Multiplex PCR | 1034 | chemotherapy | NP | 5.3 years | blood |
Ambrosone, et al. [16] | German | 2006 | Multiplex PCR | 446 | radiotherapy after surgery | skin toxicities | NP | blood |
Zárate, et al. [39] | Spain | 2007 | PCR-RFLP | 94 | chemotherapy | haematological and non-haematological | NP | blood |
Syamala, et al. [14] | India | 2008 | PCR | 347 | NP | NP | NP | blood |
Kuptsova, et al. [18] | German | 2008 | Multiplex PCR | 390 | radiotherapy after surgery | telangiectasia | 4.1 years | blood |
Bewick, et al. [19] | Canada | 2008 | PCR | 95 | chemotherapy | NP | 10.4 months | blood or bone marrow |
Tang, et al. [20] | China | 2009 | PCR | 126 | chemotherapy | NP | 6 weeks | blood |
Oliveira, et al. [21] | Brazil | 2010 | PCR-RFLP | 40 | chemotherapy | NP | NP | blood |
Yao, et al. [40] | America | 2010 | PCR-RFLP | 458 | chemotherapy | hematologic | 10.8 years | tumor cell |
Zhong, et al. [22] | China | 2010 | PCR | 132 | chemotherapy | NP | 9 weeks | blood |
Zhang (1), et al. [37] | China | 2011 | PCR-RFLP | 120 | chemotherapy | hematologic | NP | blood |
Bai, et al. [23] | China | 2012 | PCR-RFLP | 159 | chemotherapy | NP | 4 years | blood |
Terrazzino, et al. [24] | Italy | 2012 | PCR | 237 | radiotherapy | skin fibrosis | 63 days | blood |
Raabe, et al. [25] | German | 2012 | PCR-RFLP | 83 | radiotherapy | erythema | NP | blood |
Ji, et al. [26] | China | 2012 | PCR | 153 | chemotherapy | neutropenia | 51 months | blood |
Tulsyan, et al. [27] | India | 2013 | PCR-RFLP | 100 | chemotherapy | hematologic | NP | blood |
Duggan, et al. [28] | America | 2013 | PCR | 533 | surgery, surgery and radiotherapy, and chemotherapy | NP | 11.29 years | blood |
Zhang (2), et al. [38] | China | 2013 | PCR-CTPP | 219 | chemotherapy | NP | 4 years | blood |
Zhao, et al. [15] | China | 2014 | PCR | 252 | chemotherapy | hematologic | NP | blood |
Sugishita, et al. [30] | Japan | 2014 | PCR | 102 | chemotherapy | hematologic | 967 days | blood |
Liu, et al. [34] | China | 2014 | PCR | 382 | chemotherapy after surgery | NP | NP | blood |
Zhou, et al. [31] | China | 2015 | PCR | 420 | chemotherapy after surgery | NP | 5 years | blood |
Wang (1), et al. [32] | China | 2015 | PCR-RFLP | 310 | chemotherapy | NP | 5 years | blood |
Wang (2), et al. [33] | China | 2015 | PCR-RFLP | 262 | chemotherapy | NP | NP | blood |
Islam, et al. [35] | Bangladesh | 2015 | PCR-RFLP | 256 | chemotherapy | hematologic | NP | blood |
Eckhoff, et al. [36] | Denmark | 2015 | PCR | 150 | chemotherapy | docetaxel-induced peripheral neuropathy | 7.5 months | blood |
Yuan, et al. [41] | China | 2015 | PCR-RFLP | 273 | chemotherapy | NP | 5 years | blood |
PCR polymerase chain reaction, NP not provided